RXC006, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF) and other types of fibrosis, was seen to ease lung scarring in a mouse model of IPF, its developer, Redx Pharma, has announced. The investigative inhibitor is also reported to work favorably in human lung fibroblasts grown in the laboratory.
Potential Anti-Fibrotic Oral Treatment, RXC006, Shows Promise in Early Studies, Redx Announces
Middle-age adults with reduced respiratory function have up to a 27% higher risk of developing dementia or cognitive impairment later in life, a study suggests. This risk pattern is even more pronounced in patients with restrictive lung diseases such as idiopathic pulmonary fibrosis (IPF), according to the study, titled “…
When I was growing up, friends, family members, and teachers would tease me about my “fear of missing out” on opportunities. This was because I rarely turned down the chance to try something new. As I got a little older, I often committed to more than I could…
A herbal extract derived from a product used in Korean traditional medicine may be a potential alternative treatment for idiopathic pulmonary fibrosis (IPF), a mouse study suggests. The herbal extract was found to reduce inflammation and markers of lung fibrosis in a mouse model of PF…
Pulmonary fibrosis significantly increases the risk of severe pneumonitis (inflammation of lung tissue) among patients with lung cancer who were treated with Opdivo or Keytruda, a retrospective study suggests. The study “Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A…
Before my idiopathic pulmonary fibrosis (IPF) diagnosis in early 2016, I was oblivious to the importance of caring for my respiratory health. While it is easy to conclude that the respiratory system is required for human survival, I think many people take healthy lungs and the ability to…
Reduced levels of decorin proteins in the blood may be linked to a lower risk of death among patients with idiopathic pulmonary fibrosis (IPF) who have experienced acute exacerbations, researchers suggest. Their findings were reported in the study, “Serum decorin is a potential prognostic biomarker in…
Bridge Biotherapeutics filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start a Phase 1 trial of its idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 in January. BBT-877 is an inhibitor of the enzyme autotaxin (ATX). This enzyme is relevant…
I’m excited to share that my book, “Pulmonary Fibrosis Journey: A Counselor and Fellow Patient Walks with You,” was released a few days ago. It was a labor of love and I’m so glad I wrote it. Why I wrote it I was a mess when I…
Evidence that the IGFBP-5 protein contributes to the development of pulmonary fibrosis was supported by new research finding that its higher-than-normal levels in people with fibrotic disease help to drive other pro-fibrotic proteins and factors. The study, “IGFBP-5 Promotes Fibrosis via Increasing Its Own Expression and That…
